# Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

> **NCT06941025** · — · RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 10 (estimated)

## Conditions studied

- Fabry Disease
- Pregnancy
- Pregnancy Complications

## Interventions

- **OTHER:** Not applicable- observational study

## Key facts

- **NCT ID:** NCT06941025
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-23
- **Primary completion:** 2034-12
- **Final completion:** 2034-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06941025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06941025, "Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06941025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*